Tuesday, August 25, 2026
spot_img

IMCD to acquire the life science business of YCAM in South Korea and expand its footprint in the beauty and personal care markets

IMCD to acquire the life science business of YCAM in South Korea

From left to right: JaeJoong Kim, Sales Director of YCAM, Fenna van Zanten, Director M&A and member of IMCD Group Executive Committee, Munkyum Kim, CEO of YCAM, Dongjoon Lee, Managing Director of IMCD Korea, Peter Shin, Finance Director of IMCD Korea
From left to right: JaeJoong Kim, Sales Director of YCAM, Fenna van Zanten, Director M&A and member of IMCD Group Executive Committee, Munkyum Kim, CEO of YCAM, Dongjoon Lee, Managing Director of IMCD Korea, Peter Shin, Finance Director of IMCD Korea

ROTTERDAM, The Netherlands (18 December 2024) – IMCD N.V. (“IMCD” or “Company”), a global leading distribution and formulation partner of speciality chemicals and ingredients, has signed an agreement to acquire the personal care and pharmaceutical business of YCAM Corporation, a distributor based in South Korea (“YCAM”).

Founded in 2010, YCAM specialises in distributing speciality ingredients for the cosmetics, personal care, and pharmaceutical markets. YCAM represents leading global suppliers and focuses on providing customers with formulatory advice and specialty ingredients through its technical team and laboratory support, helping them to stay abreast of market trends. YCAM is located in Anyang, South Korea, and generated a revenue of approximately KRW 26 billion (ca. EUR 17 million) in 2023 with 8 employees.

“This acquisition will be an important step in expanding our footprint in our beauty and personal care market and further enriches our life science portfolio,” remarked Dongjoon Lee, Managing Director of IMCD South Korea. “We are excited to welcome such a dedicated and skilled team to IMCD.

 “I am convinced that YCAM’s extensive resources and knowledge can swiftly integrate into IMCD’s global business model, enhancing its commercial and operational strength in South Korea’s personal care and pharmaceuticals industries,” remarked Munkyum Kim, CEO of YCAM. “My team has been an invaluable asset to the company, and I believe they will have even more opportunities to develop and maximise their potential with IMCD.”
 
The closing of the transaction is subject to customary (regulatory) closing conditions and is expected to take place in the second quarter of 2025.

Attached, the full press release in PDF format, the main visual and photo caption.

Attachments

  • IMCD to acquire the life science business of YCAM in South Korea
  • Photo caption – IMCD to acquire the life science business of YCAM in South Korea
  • Press release – IMCD to acquire the life science business of YCAM in South Korea

Powered by SlickText.com

Hot this week

The Master Tape – Navigating $108 Crude Oil & Top Setups in $NVDA, $LLY, $WMB, & $CRDL 

Welcome back, traders! After a phenomenal run in 2025,...

Spirit Blockchain Capital Appoints Interim CEO and Interim CFO

VANCOUVER, BC, April 17, 2026 (GLOBE NEWSWIRE) --...

Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

BEIJING, China, April 17, 2026 (GLOBE NEWSWIRE) --...

25/2026・Trifork Group: Shareholders approve all resolutions at the Annual General Meeting 2026

Schindellegi, Switzerland – 17 April 2026 Trifork Group...

Form 8.5 (EPT/RI)- Gamma Communications Plc

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY...

Topics

spot_img

Related Articles

Popular Categories

spot_img